Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 14/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | MYC | P01106 | 1/20 | 0.33 |
| ▸ | MAX | P61244 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14941105 | 1.00 | PIN1 (0.38) | PIN1ALDH1A1NPC1CYP3A4MAPT | |
| SCHEMBL22769970 | 0.83 | PIN1 (0.42) | PIN1ALDH1A1MAPT | |
| SCHEMBL14940745 | 0.80 | PIN1 (0.36) | PIN1NPC1CYP3A4MAPTHTT | |
| SCHEMBL13150902 | 0.79 | PIN1 (0.35) | PIN1 | |
| SCHEMBL27847311 | 0.79 | PIN1 (0.34) | PIN1ALDH1A1MAPT | |
| SCHEMBL4087952 | 0.78 | PIN1 (0.35) | PIN1ALDH1A1MAPT | |
| SCHEMBL10286671 | 0.77 | PIN1 (0.36) | PIN1ALDH1A1 | |
| SCHEMBL27894803 | 0.77 | PIN1 (0.38) | PIN1ALDH1A1MYCMAX | |
| SCHEMBL30823384 | 0.77 | PIN1 (0.37) | PIN1ALDH1A1 | |
| SCHEMBL1288351 | 0.76 | PIN1 (0.35) | PIN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9351974-B2 | Substituted pteridinones for the treatment of cancer | OSI Pharmaceuticals, LLC (US) | 2016-05-31 | — | — | US | disclosed |
| US-9351974-B2 | Substituted pteridinones for the treatment of cancer | OSI Pharmaceuticals, LLC (US) | 2016-05-31 | — | — | US | disclosed |
| US-9351974-B2 | Substituted pteridinones for the treatment of cancer | OSI Pharmaceuticals, LLC (US) | 2016-05-31 | — | — | US | disclosed |
| US-20140315911-A1 | DIHYDROPTERIDINONES | OSI Pharmaceuticals, LLC | 2014-10-23 | — | — | US | disclosed |
| US-20140315911-A1 | DIHYDROPTERIDINONES | OSI Pharmaceuticals, LLC | 2014-10-23 | — | — | US | disclosed |
| US-20140315911-A1 | DIHYDROPTERIDINONES | OSI Pharmaceuticals, LLC | 2014-10-23 | — | — | US | disclosed |
| EP-2776444-A1 | DIHYDROPTERIDINONES | OSI Pharmaceuticals, LLC (US) | 2014-09-17 | — | — | EP | disclosed |
| WO-2013071217-A1 | DIHYDROPTERIDINONES | OSI Pharmaceuticals, LLC (US) | 2013-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315911-A1 | DIHYDROPTERIDINONES | DHPS, DHODH, HYPK | PIN1 602/4885ALDH1A1 1118/4885NPC1 556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.